Market Place
News Type
Upload your Marketing & Sales content on your company Virtual Booth, click HERE
X
Details:
Through four and a half years, TAK-003 (9vHPV vaccine) demonstrated 84.1% vaccine efficacy (VE) (95% CI: 77.8, 88.6) against hospitalized dengue, with 85.9% VE (78.7, 90.7) in seropositive individuals and 79.3% VE (63.5, 88.2) in seronegative individuals.
Lead Product(s): 9vHPV Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: TAK-003
Highest Development Status: Phase III Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 09, 2022
Details:
Chugai, a strategic partner of Roche, updated that it will discontinue its development of AT-527 in Japan, an investigational RNA polymerase inhibitor for COVID-19. The development will be continued by Atea after the Roche announcement to terminate the partnership of joint development.
Lead Product(s): Bemnifosbuvir
Therapeutic Area: Infections and Infectious Diseases Product Name: AT-527
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Atea Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 16, 2021
Details:
The results of the SOLSTICE trial are promising and show that maribavir may help with post-transplant CMV viremia, including cases of drug-resistance for which there is an unmet need.
Lead Product(s): Maribavir
Therapeutic Area: Infections and Infectious Diseases Product Name: SHP620
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: SHIRE LLC
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 21, 2021
Details:
The study sought to find out whether the hIVIG could reduce the risk of disease progression when added to standard of care treatment including remdesivir in hospitalized patients at risk for serious complications.
Lead Product(s): Hyperimmune immunoglobulin
Therapeutic Area: Infections and Infectious Diseases Product Name: hIVIG
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: National Institutes of Health
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 02, 2021
Details:
More than three times as many transplant recipients with confirmed resistant cytomegalovirus (CMV) infection at baseline receiving the investigational drug Maribavir achieved cmv viremia clearance compared to conventional antiviral therapies.
Lead Product(s): Maribavir
Therapeutic Area: Infections and Infectious Diseases Product Name: TAK-620
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 15, 2021
Details:
Japan has approved Avigan, known generically as favipiravir, as an emergency flu medicine. But concerns remain, as the drug has been shown to cause birth defects in animal studies and its effectiveness against COVID-19 has proven difficult to demonstrate.
Lead Product(s): Favipiravir
Therapeutic Area: Infections and Infectious Diseases Product Name: Avigan
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 21, 2021
Details:
The meta-analysis of nine clinical trials showed the drug, known generically as favipiravir, helped patients early on in their hospitalisation but failed to demonstrate statistically significant results in reducing mortality among those with mild to moderate COVID-19.
Lead Product(s): Favipiravir
Therapeutic Area: Infections and Infectious Diseases Product Name: Avigan
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 18, 2021
Details:
More than twice as many transplant recipients with R/R CMV infection/disease treated with maribavir achieved confirmed CMV viremia clearance at Study Week 8, the study’s primary endpoint, as compared to 23.9% of those on conventional antiviral therapies.
Lead Product(s): Maribavir
Therapeutic Area: Infections and Infectious Diseases Product Name: TAK-620
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 12, 2021
Details:
Phase 3 clinical trial evaluating the efficacy and safety of the investigational drug TAK-620 (maribavir), in the treatment of transplant recipients with refractory/resistant cytomegalovirus (CMV) infection met its primary endpoint.
Lead Product(s): Maribavir
Therapeutic Area: Infections and Infectious Diseases Product Name: TAK-620
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 04, 2020
Details:
Foipan® Tablets is an oral protease enzyme inhibitor created internally at ONO, and obtained a manufacturing and marketing approval in 1985 for the alleviation of acute symptoms associated with chronic pancreatitis.
Lead Product(s): Camostat
Therapeutic Area: Infections and Infectious Diseases Product Name: Foipan
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 09, 2020
